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Abstract
Background: Histone deacetylases (HDACs) are known to be associated with an overexpression in different types
of cancer such as colon and prostate cancer. In this study we aimed to evaluate the protein expression of class I
HDACs in urothelial carcinoma of the bladder.
Methods: A tissue microarray containing 348 tissuesamples from 174 patients with a primary urothelial carcinoma
of the bladder was immunohistochemically stained for HDAC 1, 2 and 3. Intensity of staining was evaluated and the
association with clinico-pathological features and prognosis was assessed.
Results: High HDAC expression levels were found in 40 to 60% of all investigated urothelial carcinomas (HDAC-1:
40%, HDAC-2: 42%, HDAC-3: 59%).
HDAC-1 and HDAC-2 were significantly associated with higher tumour grades.
Although all three markers could not predict progression in univariate analyses, high HDAC-1 expression was
associated with a trend toward poorer prognosis. Patients with high-grade tumours and high expression levels of
HDAC-1 were more likely to progress compared to all other patients (p < 0.05).
Conclusions: High-grade noninvasive papillary bladder tumours are associated with high expression levels of
HDAC-1 and HDAC-2. High grade tumours in combination with high expression of HDAC-1 showed a worse
prognosis than the other tumours. The high expression levels of HDACs observed particularly in high grade
urothelial bladder cancer clearly warrant subsequent studies on the potential use of HDAC inhibitors as a novel
therapeutic approach.
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Background
The majority of bladder cancer patients (75-80%) ini-
tially present with papillary noninvasive (pTa) or superfi-
cially invasive (pT1) urothelial carcinoma, whereas the
remaining 20-25% of primary tumours are already muscle
invasive (≥ pT2) at first diagnosis [1,2].
Among superficial tumours, almost 70% recur after
transurethral resection and up to 25% of them show pro-
gression into a muscle invasive disease [3]. Bladder cancer
patients have to be monitored closely for disease recur-
rence and progression, which contributes to the high costs
of this disease. Therefore there is a great interest in identi-
fying markers that can diagnose superficial cancer with a
high risk of progression and allow for more specific sur-
veillance strategies [4]. So far no established marker allows
prediction of tumour progression.
Histone deacetylases (HDACs) constitute a family of
enzymes that deacetylate histones and other cellular pro-
teins. They are major regulators of transcription and are
also important in other cellular processes [5]. HDACs
are classified into four different classes based on the
phylogenetic analysis of their structure and homology to
yeast enzymes [6]. Class I HDACs are divided into four
isoforms (HDAC-1, −2, −3 and −8) and are known to be
associated with an overexpression in different types of
cancer such as colon and prostate cancer [7,8]. Pub-
lished expression array data for urothelial cancer could
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demonstrate an overexpression of different class I HDACs
compared to normal urothelium. Especially, the first three
isoforms HDAC-1, −2 and −3 were found to be overex-
pressed. Contrary to HDAC-8, for which no overexpres-
sion was found [2,9-12]. In contrast to these findings, a
more recent study of Xu and colleagues reported no dif-
ference of expression in the expression levels of HDAC-2
between normal urothelial and bladder cancer tissue as
assessed by immunohistochemistry [13]. Few studies have
found an effect for HDAC-inhibitors (HDAC-i) in urothe-
lial cancer cell lines [12,14-17], however, a broad expres-
sion analysis of HDACs in urothelial carcinomas has not
been conducted so far. In addition, there is no study
available on the prognostic relevance of class I HDACs in
bladder cancer. We aimed to analyse the expression pat-
terns of the most promising class I HDACs (HDAC-1, −2
and −3) in a representative cohort of primary bladder
cancers and correlated these to clinico-pathological pa-
rameters including tumour stage, grade, multifocality,
adjacent carcinoma in situ, growth pattern and finally
clinical follow-up data.
Methods
Bladder cancer tissue microarray (TMA)
Tissue microarrays (TMA) contained 348 formalin-fixed,
paraffin-embedded urothelial bladder cancer tissues
from 174 patients and were constructed as previously
described [18]. All tumour samples were represented in
duplicate tissue cores (1 mm). The TMA consisted of
tumour tissues only, normal urothelial samples were not
available. Specimens were collected between 1990 and
2006 by the Institute of Surgical Pathology, University of
Zurich, Switzerland. The TMA includes a series of 174
consecutive (non-selected) primary urothelial bladder
tumours. Finally, the TMA contained 90 pTa, 68 pT1
and 16 ≥ pT2 tumours. Hematoxylin and eosin–stained
slides of all specimens were reevaluated by two experi-
enced pathologists (BJ, GK).
Tumour stage and grade were assigned according to
UICC and WHO criteria.
Retrospective clinical follow-up data were available for
all of 174 patients (100%). The median follow-up period
for the entire cohort was 110.6 months (range 32.4 to
266.8 months). Clinico-pathologic data are summarized
in Table 1. The study was approved by the local scien-
tific ethics committee Kantonale Ethikkommission Zürich
(http://www.kek.zh.ch/, approval no.: StV-Nr. 25/2007).
Immunohistochemistry
The TMA was freshly cut (3 μm). For immunohistochemi-
cal detection of HDAC-1, −2 and −3 isoforms on tissue
samples, prediluted polyclonal rabbit IgG antibody directed
against HDAC-1 (1:11, Abcam, Cambridge, UK), monoclo-
nal mouse IgG antibody directed against HDAC-2 (1:5000,
Table 1 Patient and tumor characteristics and results of
molecular and immunohistochemical analyses
Variable Categorization n analyzable %
Total n = 174
Clinico-pathologic data:
Age at diagnosis (median, range) 69,5 years (32–92)
<70 years 87 50.0
≥70 years 87 50.0
Sex
Female 43 24.7
Male 131 75.3
Tumor stage (WHO 1973a)
pTa 90 51.7
pT1 68 39.1
pT2 13 7.5
pT3 2 1.1
pT4 1 0.6
Histologic grade (WHO 1973a)
G1 44 25.3
G2 87 50.0
G3 43 24.7
Histologic grade (WHO 2004b)
Low grade 101 58.0
High grade 73 42.0
Adjacent carcinoma in situ
No 158 90.8
Yes 16 9.2
Multiplicity
Solitary 124 71.3
Multifocal 50 28.7
Growth pattern
Papillary 159 91.4
Solid 15 8.6
Immunohistochemistry (IHC):
HDAC-1
Low expression 104 59.8
High expression 70 40.2
HDAC-2
Low expression 101 58.0
High expression 73 42.0
HDAC-3
Low expression 71 40.8
High expression 103 59.2
aStaging and grading according to the 1973 WHO classification system.
bStaging and grading according to the 2004 WHO classification system.
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Abcam) and monoclonal mouse IgG antibody directed
against HDAC-3 (1:500, Becton Dickinson, Franklin
Lakes, NJ, USA) was used on 3 μm paraffin sections, as
described [19]. Ki-67 was detected with clone MIB-1
(Dako, Glostrup, Denmark; dilution 1:50).
Immunohistochemical studies utilised an avidin-biotin
peroxidase method with a diaminobenzidine (DAB) chro-
matogen. After antigen retrieval (microwave oven for
30 min at 250 W) immunohistochemistry was carried
out in a NEXES immunostainer (Ventana, Tucson, AZ)
following manufacturer’s instructions.
Evaluation of Immunohistochemistry
One surgical pathologist (BJ) evaluated the slides under
the supervision of the senior author. Nuclear staining of
HDAC isoforms was scored applying a semiquantitative
immunoreactivity scoring (IRS) system that incorporates
the percentual area and the intensity of immunoreactiv-
ity resulting in a score ranging from 0 to 12, as described
previously [19]. For statistical analysis, the intensity of
HDAC expression was grouped into low vs. high rates of
expression. Cases exhibiting an IRS from 0–8 were
pooled in a HDAC low expression group whereas cases
with a higher IRS (9–12) were designated HDAC high
expression group. The percentage of Ki-67 positive cells
of each specimen was determined as described previously
[20]. High Ki-67 labelling index was defined as more than
10% of positive tumour cells [21].
Statistical analysis
Statistical analyses were performed with SPSS version
20.0 (SPSS Inc, Chicago, IL). Differences were considered
significant if p < 0.05. To study statistical associations be-
tween clinicopathologic and immunohistochemical data,
contingency table analysis and 2-sided Fisher’s exact tests
were used. Univariate Cox regression analysis was used to
evaluate statistical association between clinicopathologic/
immunohistochemical data and progression free survival
(PFS). PFS curves were calculated using the Kaplan–Meier
method with significance evaluated by 2-sided log-rank
statistics. For the analysis of PFS, patients were censored
at the date when there was a stage-shift (from Ta to T1-4,
respectively from T1 to T2-T4), or if there was distant
metastatic disease.
A B
Figure 1 Immunohistochemical staining with HDAC-1. (A) low expression HDAC-1 staining pattern in a low-grade urothelial tumour; (B) high
expression HDAC-1 staining pattern in a typically high-grade urothelial tumour.
A B
Figure 2 Immunohistochemical staining with HDAC-2. (A) low expression HDAC-2 staining pattern in a low-grade urothelial tumour; (B) high
expression HDAC-2 staining pattern in a typically high-grade urothelial tumour.
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Results
Staining patterns of HDAC1-3
HDAC 1–3 protein expression in bladder cancer tissue
samples was investigated by immunohistochemical ana-
lysis of the TMA containing 174 specimens from patients
with a primary urothelial carcinoma of the bladder. All
174 (100%) patients could be evaluated for HDAC immu-
nostaining. All three investigated HDACs showed high
expression levels in 40 to 60% of all tumours. Figures 1, 2
and 3 represent examples of typical exclusively nuclear
staining patterns of HDAC-1, −2 and −3 (low - and high
expression). For HDAC-1 40% of the tumours showed
A B
Figure 3 Immunohistochemical staining with HDAC-3. (A) low expression HDAC-3 staining pattern in a low-grade urothelial tumour; (B) high
expression HDAC-3 staining pattern in a typically high-grade urothelial tumour.
Table 2 Associations of the HDAC-1, −2 and 3 and Ki-67 with pathologic characteristics (n = 174)
Variable Categorization HDAC-1 expression HDAC-2 expression HDAC-3 expression Ki-67 expression
Low High p Low High p Low High p Low High p
Tumor stage (WHO 1973)a
pTa 59 31 0.162 55 35 0.811 37 53 0.257 71 19 <0.001
pT1 37 31 37 31 30 38 35 33
pT2 5 8 7 6 2 11 2 11
pT3 2 0 1 1 1 1 0 2
pT4 1 0 1 0 1 0 0 1
Histologic grade (WHO 1973)a
G1 29 15 0.022 32 12 0.026 20 24 0.425 39 5 <0.001
G2 57 30 50 37 37 50 61 26
G3 18 25 19 24 14 29 8 35
Histologic grade (WHO 2004)b
Low grade 71 30 0.001 68 33 0.005 49 52 0.019 87 14 <0.001
High grade 33 40 33 40 22 51 21 52
Adjacent carcinoma in situb
No 96 62 0.432 96 62 0.032 65 93 1.00 105 53 <0.001
Yes 8 8 5 11 6 10 3 13
Multiplicityb
Solitary 79 45 0.124 77 47 0.093 49 75 0.587 86 38 0.003
Multifocal 25 25 24 26 22 28 22 28
Growth patternb
Papillary 97 62 0.278 94 65 0.416 65 94 1.00 107 52 <0.001
Solid 7 8 7 8 6 9 1 14
aChi-Square Pearson (2-sided); bold face representing p-values < 0.05.
bFisher’s exact test (2-sided); bold face representing p-values < 0.05.
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high expression levels, for HDAC-2 42% and for HDAC-3
even 59% (Table 1).
Correlations to clinico-pathological parameters
HDAC-1 to 3 and Ki-67 were correlated with clinico-
pathologic characteristics (stage, grading, adjacent car-
cinoma in situ, multiplicity and growth pattern) of the
tumours (Table 2). Strong staining of HDAC-1 and
HDAC-2 was associated with higher grading (both WHO
1973 and 2004), additionally tumours with high expres-
sion levels of HDAC-2 presented more often with ad-
jacent carcinoma in situ compared to tumours with weak
HDAC-2 staining. High expression levels of HDAC-3
were only associated with higher tumour grade according
the new WHO 2004 grading system. Ki-67 showed a sig-
nificant correlation with all clinico-pathologic charac-
teristics (p < 0.05), except for tumour multiplicity. The
expression levels of all three tested HDAC proteins were
significantly associated with each other (data not shown).
Furthermore, strong staining of all three HDACs corre-
lated with high Ki-67 labelling index (for HDAC-1: Spear-
mans Rho rs = 0.325, p < 0.001, for HDAC-2: rs = 0.271,
p < 0.001; for HDAC-3: rs = 0.191, p < 0.05).
Univariate progression analyses
A total of 158 patients underwent TUR for a primary Ta
or T1 urothelial carcinoma of the bladder and were
followed for a median of 110.7 month (range: 32.4 -
245.9 month). In this group, only high expression levels
of Ki-67 were significantly associated with increased
risk of progression (p < 0.01). Increased expression of
HDAC-1 showed a tendency for higher progression rates,
however this was not statistically significant (p = 0.085).
Beside growth pattern none of the clinicopathological
parameters were associated with PFS. Table 3 shows
p-values for the pathological data and the molecular
markers.
To test whether the combination of high expression
levels of HDAC-1 & HDAC-2 with different known
clinico-pathological parameters can predict prognosis we
performed an univariate cox-regression analysis. The
combination of high-grade tumours and high expression
levels of HDAC-1 was a predictor of PFS (hazard ratio
[HR], 1.640; 95% confidence interval [95% CI], 1.021-
2.636; p = 0.044). However, this combination did not out-
perform tumor growth pattern or Ki-67 as a predictor of
outcome. Both parameters were able to predict progno-
sis in univariate analysis (Table 3). The combination of
HDAC-1 and growth pattern or HDAC-1 and Ki-67
were of no additional value to predict prognosis. In both
cases the p-values were higher than for growth pattern
or Ki-67 alone (data not shown).
Kaplan-Meier analyses for PFS are depicted in Figures 4,
5, 6, and show that bladder cancer patients with the
combined feature of high grade tumours and high expres-
sion pattern of HDAC-1 have a significantly shorter pro-
gression free survival than all other patients (Figure 4).
High HDAC-1 expression alone showed a tendency for
shorter PFS, although not statistically significant (Figure 5).
In addition, patients with high expression levels of Ki-67
have a significantly shorter PFS (Figure 6).
Table 3 Univariate analyses of disease progresssion
(n =158)
Variable Categorization Tumor progression
na events pb
Pathologic data:
Tumor stage (WHO 1973c)
pTa 85 10 0.412
pT1 68 12
Histologic grade (WHO 1973c)
G1 43 3 0.093
G2 82 12
G3 28 7
Histologic grade (WHO 2004d)
Low grade 95 10 0.092
High grade 58 12
Adjacent carcinoma in situ
No 141 20 0.570
Yes 12 2
Multifocality
Unifocal tumor 111 15 0.486
Multifocal tumor 42 7
Growth pattern
Papillary 146 17 <0.0001
Solid 7 5
Immunohistochemistry:
HDAC-1
Low expression 92 9 0.085
High expression 61 13
HDAC-2
Low expression 88 12 0.628
High expression 65 10
HDAC-3
Low expression 65 8 0.754
High expression 88 14
Ki-67 IHC
Low expression 101 9 0.004
High expression 52 13
aOnly primary pTa and pT1 tumours are included.
bLog Rank test (2-sided); bold face representing p-values <0.05.
cStaging and grading according to the 1973 WHO classification system.
dStaging and grading according to the 2004 WHO classification system.
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Discussion
This is the first comprehensive immunohistochemical
analysis of the expression of several class I HDAC pro-
teins (1, 2 and 3) in urothelial carcinoma. In our study,
we found all three isoforms in a relevant amount of all
investigated urothelial tumours. HDAC-1 and HDAC-2
were highly associated with high-grade superficial papillary
bladder tumours. Additionally, high expression levels of
HDAC-1 showed a tendency towards a shorter PFS.
So far, little was known about class I HDAC expression
pattern in urothelial cancer [5]. According to the Proteina-
tlas (http://www.proteinatlas.org), HDAC-1 to −3 expression
levels are moderate at most in urothelial cancer [22]. In
previous expression arrays HDAC-2 and −3 showed
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Figure 4 Kaplan-Meier analyses for progression-free survival for group of high-grade tumours in combination with high expression
levels of HDAC-1 vs. high- and low-grade tumours with low expression levels of HDAC-1. For statistical analysis for survival curves
Log-Rank test was used.
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Figure 5 Kaplan-Meier analyses for progression-free survival for HDAC-1 staining. For statistical analysis for survival curves Log-Rank test
was used.
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higher expression levels in urothelial cancer than in nor-
mal urothelial tissue [2,9,11]. Expression array data from
another study by Wild et al. demonstrated an upregulation
of HDAC-1 in bladder cancer compared to normal
urothelial tissue [23]. On the contrary, published data
from other groups did not reveal any difference of class I
HDAC expression between urothelial cancer and normal
urothelium in microarray data [24,25]. In accordance with
these findings a study from Xu reported no difference in
immunohistochemical expression of HDAC-2 in human
bladder cancer tissue (142 cases) compared to normal
urothelial tissue (23 cases) [13].
In a recent study, Niegisch and colleagues were able to
show upregulation of HDAC-2 mRNAs in a subset of
tested tumours compared to normal urothelium [9,11,17].
However, only 24 tumour tissues and 12 normal samples
were tested.
Our study is the first attempt to test the immunohisto-
chemical expression of class I HDACs in a large cohort
of patients with bladder cancer. As class I HDACs can
be detected in a relevant group of urothelial cancer, they
may therefore be relevant in pathophysiology and as tar-
get proteins for treatment.
Besides the distinct presence of class I HDACs in urothe-
lial cancer, high expression levels of HDAC-1 and −2 were
associated with stage and grade of this tumours. Overex-
pression of HDACs has been found in several other solid
tumours such as prostate and colon cancer [7,26,27]. High
expression levels of class I HDACs correlated with tumour
dedifferentiation and higher proliferative fractions (mea-
sured by Ki-67) in urothelial carcinoma, which is in line
with in vitro studies showing that high HDAC activity
leads to tumour dedifferentiation and enhanced tumour
cell proliferation [28-30]. Despite the growth inhibi-
tory effects of HDAC-i demonstrated in various cell lines
including bladder cancer cells, a broad expression ana-
lysis of this attractive target has not been conducted
yet [12-16,31,32].
To the best of our knowledge, this is the first study
analysing HDAC-1, −2 and −3 expression in bladder
cancer and its association to prognosis. In our study
HDAC-1 was found to be of rough prognostic relevance
in pTa and pT1 tumours. High expression levels of class
I HDACs have been found to be of prognostic relevance
in other tumour entities before. Other study groups pre-
viously reported the association of class I HDACs with
more aggressive tumours and even shortened patient
survival in prostate and gastric cancer [7,33]. Our find-
ings suggest that HDAC-1 may have a role in prognosis
of superficial urothelial tumours.
In our work the rate of Ki-67 positive tumour cells
was highly associated with tumour grade, stage, and a
shorter PFS. A substantial amount of research has demon-
strated the prognostic role of Ki-67 in urothelial cancer;
its prognostic value and its association with pathological
parameters and prognosis could be shown in several stud-
ies [34-36]. These findings are in line with our work and
confirm the representativeness and validity of this TMA-
construct. Furthermore, we observed a strong correlation
between the proliferation index (Ki-67) and all three in-
vestigated HDACs. The connection between HDAC ex-
pression and Ki-67 observed in urothelial carcinoma has
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already been demonstrated for prostate, renal and colorec-
tal cancer in previous studies [7,19,37].
Additionally, intravesical instillation of HDAC-i may
have a potential as chemopreventive agent to treat superfi-
cial bladder cancer, as up to 50% of superficial tumours
showed high expression levels of HDACs. However, it is
not clear whether HDAC protein expression as assessed
by immunohistochemistry is a predictor for treatment re-
sponse to HDAC-i. Thus, additional studies are needed to
clarify the role HDAC-i in non-invasive urothelial cancer.
Our study has several limitations, including its retro-
spective design and the use of immunohistochemical
methodology, which has inherent limitations, including
scoring of staining. We used a standardized and well-
established semiquantitative scoring method in accord-
ance with previous publications to reduce variability. In
addition, the proportion of muscle-invasive bladder can-
cer was limited and as a consequence we cannot draw
any conclusion for this subgroup of tumours. Therefore
future research should also try to assess whether class I
HDACs have a prognostic value in locally advanced in-
vasive or metastatic urothelial cancer.
Conclusion
High levels of class I HDACs showed a significant cor-
relation with cellular proliferation and tumor grade.
Non-invasive (pTa) and pT1 bladder tumours with high
expression levels of HDAC-1 showed a tendency towards
shorter PFS in our cohort. However, further prospective
studies and bigger cohorts including muscle-invasive blad-
der cancer patients are needed to evaluate the prognostic
value of HDACs. Moreover the high expression levels of
HDACs in urothelial bladder cancer might be indicative
for a treatment response to HDAC-i which ought to be
evaluated in further studies.
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